Charles River Laboratories International, Inc.
General ticker "CRL" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $8.0B (TTM average)
Charles River Laboratories International, Inc. follows the US Stock Market performance with the rate: 61.4%.
Estimated limits based on current volatility of 1.3%: low 210.61$, high 216.30$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 20100 as of 2024
- US accounted for 55.3% of revenue in the fiscal year ended 2024-12-28
- Top business risk factors: Operational and conduct risks, Technology integration issues, Strategic risks and growth management, Realizing cost savings, Geopolitical risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-28 to 2026-12-28
- 2024-12-28 to 2025-12-28 estimated range: [147.21$, 221.01$]
- 2025-12-28 to 2026-12-28 estimated range: [143.37$, 216.23$]
Financial Metrics affecting the CRL estimates:
- Negative: with PPE of 18.0 at the end of fiscal year the price was high
- Positive: 6.66 < Operating cash flow per share per price, % of 7.68
- Positive: -5.04 < Operating profit margin, % of 5.61
- Positive: 42.77 < Shareholder equity ratio, % of 45.98 <= 64.37
- Positive: Industry inventory ratio change (median), % of -0.48 <= -0.18
- Positive: -3.56 < Return on assets ratio (scaled to [-100,100]) of 0.33
- Negative: negative Industry operating cash flow (median)
Short-term CRL quotes
Long-term CRL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-28 |
|---|---|---|---|
| Operating Revenue | $3,976.06MM | $4,129.41MM | $4,049.99MM |
| Operating Expenses | $3,325.09MM | $3,512.15MM | $3,822.64MM |
| Operating Income | $650.98MM | $617.26MM | $227.35MM |
| Non-Operating Income | $-27.99MM | $-35.98MM | $-134.23MM |
| Interest Expense | $59.29MM | $136.71MM | $126.29MM |
| Income(Loss) | $622.99MM | $581.28MM | $93.11MM |
| Taxes | $130.38MM | $100.91MM | $67.82MM |
| Profit(Loss)* | $486.23MM | $474.62MM | $10.30MM |
| Stockholders Equity | $2,976.29MM | $3,596.88MM | $3,461.50MM |
| Inventory | $255.81MM | $380.26MM | $278.54MM |
| Assets | $7,602.77MM | $8,195.00MM | $7,528.35MM |
| Operating Cash Flow | $619.64MM | $683.90MM | $734.58MM |
| Capital expenditure | $324.73MM | $318.53MM | $232.97MM |
| Investing Cash Flow | $-607.92MM | $-563.15MM | $-245.09MM |
| Financing Cash Flow | $-42.40MM | $-85.52MM | $-550.93MM |
| Earnings Per Share** | $9.57 | $9.27 | $0.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.